Combination of two antibodies prevents growth and spread of triple-negative breast tu

[News]

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

More... (http://www.news-medical.net/news/20130210/Combination-of-two-antibodies-prevents-growth-and-spread-of-triple-negative-breast-tumors.aspx)